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Background: Inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn’s 27	
disease are diseases with impaired epithelial barrier function. We aimed to investigate 28	
whether mutated prostasin and thus, reduced colonic epithelial sodium channel (ENaC) 29	
activity predispose to develop an experimentally dextran sodium sulfate (DSS)-induced colitis.  30	
Methods: Wildtype, heterozygous (frCR/+) and homozygous (frCR/frCR) prostasin mutant rats 31	
were treated 7 days with DSS and 7 days of recovery and analysed with respect to histology, 32	
clinicopathological parameters, inflammatory marker mRNA transcript expression, and 33	
sodium transporter protein expression. 34	
Results: In this study, a more detailed analysis on rat frCR/frCR colons revealed reduced 35	
number of crypt and goblet cells, and local angiodysplasia, as compared to heterozygous 36	
(frCR/+) and wildtype littermates. Following 2% DSS treatment for 7 days followed by 7 days 37	
recovery, frCR/frCR animals lost body weight, and reached maximal diarrhea score and highest 38	
disease activity after only 3 days, and strongly increased cytokine levels. The histology score 39	
significantly increased in all groups, but frCR/frCR colons further displayed pronounced 40	
histological alterations with near absence of goblet cells, rearrangement of the lamina propria 41	
and presence of neutrophils, eosinophils, and macrophages. Additionally, frCR/frCR colons 42	
showed ulcerations and edemas, that were absent in frCR/+ and wildtype littermates. 43	
Following recovery, frCR/frCR rats reached, although significantly delayed, near-normal 44	
diarrhea score and disease activity, but exhibited severe architectural remodelling, despite 45	
unchanged sodium transporter protein expression.  46	
Conclusions: In summary, our results demonstrate a protective role of colonic prostasin 47	
expression against experimental colitis, and thus represents a susceptibility gene in the 48	
development of IBD.   49	
 50	
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 52	
Introduction  53	
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory diseases with chronic 54	
defects of the gastrointestinal tract, leading to severe bloody diarrhea, abdominal pain and 55	
rectal bleeding in patients affected by this class of disorders.1 While the understanding of the 56	
structural changes associated with inflammatory bowel diseases (IBD) have progressed, the 57	
molecular basis and pathways implicated in the disease remain largely unknown. The 58	
intestinal mucosa plays a crucial role in the transport of molecules across the epithelium as 59	
well as in the immune protection of the intestinal tract by participating in the coordinated 60	
communication between the external environment and the immune system.2 When inflamed 61	
after epithelial injury, the mucosa loses its barrier function, leading to water loss in the stool, 62	
and to impaired ionic and molecular transport. Inflammation of the intestinal tract and chronic 63	
colitis can be induced by chemical compounds like e.g., the administration of Dextran sodium 64	
sulfate (DSS).3-5 Various animal models of chronic colitis show increased permeability of the 65	
intestinal mucosa, likely because of epithelial damage and tight junction injury.6,7 DSS 66	
treatment itself of BALB/c mice leads to the loss of the tight junction protein ZO-1 and 67	
increased epithelial permeability.7 68	
In patients, increased colonic epithelial permeability was reported that preceded the onset of 69	
IBD.8-10 Indeed, an increasing number of genes are linked to intestinal permeability, immunity, 70	
protection from pathogens and solute transport, like e.g. claudins,11 tumor necrosis factor a 71	
(TNFa),12 interleukins,13 or the epithelial sodium channel (ENaC)14 and thus as associated 72	
with IBD, either as susceptibility genes or through their protective role. Indeed, in colonic 73	
epithelial preparations from UC patients, decreased electrogenic sodium transport was 74	
measured as compared to colonic preparations from healthy patients, most likely through 75	
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reduced β- and γ-ENaC mRNA transcript expression levels.14 Pre-incubation of rat colonic 76	
epithelial preparations with either TNFa or IL-1b decreases ENaC-mediated electrogenic 77	
sodium transport and inhibits the transcription of b- and g-ENaC.11,15 78	
The membrane-bound serine protease prostasin (CAP1/Prss8) was previously identified as a 79	
channel activating protease (CAP), since it increases ENaC-mediated sodium currents by 80	
increasing the open probability (PO) of single channels when co-expressed in the Xenopus 81	
oocyte expression system.16-18 In vivo, prostasin mutations result in embryonic lethality19,20 or 82	
reduced embryonic viability, skin defects (including epidermal barrier impairment, leading to 83	
early postnatal lethality due to severe skin dehydration as a consequence of tight junction 84	
defects)19,21 and decreased ENaC activity as measured in colon.21 ENaC therefore determines 85	
the body sodium homeostasis.22 As a consequence of the reduced epithelial sodium transport 86	
in adulthood, the resolution of pulmonary edema in cases of lung injury is significantly 87	
delayed,23 while in colon, animals develop a salt-losing syndrome with mineralocorticoid 88	
resistance.24  89	
We previously reported in the frCR rat model, that harbors a 16 base pairs in-frame deletion in 90	
the prostasin gene resulting in a G54-P57 deletion in the prostasin protein,25,26 decreased 91	
protease activity along with increased water loss through the skin and the presence of mild 92	
diarrhea,21 suggesting an impaired barrier function in the colon8 and decreased ENaC activity. 93	
In the present study, we aimed to investigate whether reduced prostasin activity and/or 94	
reduced ENaC expression predispose to experimentally-induced colitis, and the implication of 95	
prostasin in maintaining the intestinal barrier function. Our results demonstrate that intestinal 96	
prostasin (CAP1/Prss8) (i) preserves the colonic integrity, (ii) protects against DSS-induced 97	
inflammation, and (iii) likely protects against tissue remodeling.  98	
 99	
Material and methods 100	
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Animals 101	
Age-matched 3 months old +/+ (wild-type), frCR/+ (heterozygous), and frCR/frCR (homozygous 102	
mutant) male and female littermates were used for all experiments. Genotyping was 103	
performed as previously described.26 104	
The animals were housed in a temperature- and 60% humidity-controlled environment with a 105	
12h light/dark cycle, and had free access to food and water if not under experimentation. All 106	
experiments were approved by Swiss federal guidelines and local authorities. 107	
 108	
Induction of Colitis 109	
Colitis was induced as previously described.3,6,27, Briefly, a 2% (m/v) solution of dextran 110	
sodium sulfate (Mol.wt. 36000-50000, MP Biologicals, LLC, Illkirch Cedex, France) in tap 111	
water was daily prepared and administered ad libitum during 7 days, followed by 7 days of 112	
recovery with normal drinking water. During the 14 days of experimentation, body weight, 113	
diarrhea, and presence of occult blood in the feces (Guaiac test, HEMDETECT, DIPROmed 114	
GmbH, Weigelsdorf, Austria) were daily assessed. The attributed score for diarrhea was : 0, 115	
no diarrhea ; 1, mild diarrhea ; 2, severe diarrhea ; 3, mild diarrhea with blood ; 4, severe 116	
diarrhea with blood. The animals were sacrificed at the end of the experiment, and colon 117	
length was measured (anus to caecum). The disease activity index was calculated as 118	
previously described.27  119	
 120	
Histological Analysis 121	
Distal colons were fixed in 4% paraformaldehyde and further processed for paraffin 122	
embedding. 3µm sagittal sections were cut and dried 15 minutes at 60°C. The paraffin was 123	
removed and the slides re-hydrated as following : Xylol 2x5 min., ethanol 100% 2x1 min., 124	
ethanol 95% 1 min., and water. The H&E staining was performed as follows : Glychemalun 125	
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solution (Hematein 0.013M, Gurr #34036 ; potassium alum 0.3133M, Merck #1047 ; glycerol 126	
30% ; acetic acid 1%, Merck #1.00063) for 4 minutes, tap water with acid alcohol 1% for 3 127	
seconds, tap water for 15 seconds, water plus few drops of NH3 together with tap water, 128	
erythrosine solution 0.2% (Erythrosin 0.0023M, Merck #15936 ; formol 0.1%, Merck #4003) 129	
for 30 seconds, and tap water. Alcian blue (AB) staining was performed as follows : alcian 130	
blue (DIAPATH C0052) for 20 minutes, tap water, nuclear stain for 3 minutes (Waldeck, 2E-131	
01), and water. Slides were dehydrated by following steps ethanol 70% to xylol and mounted 132	
(Eukitt, Hatfield, PA). Pictures were taken using an Axion HRC (Carl Zeiss MicroImaging 133	
Inc.). The histology score to quantify the degree of intestinal inflammation was calculated as 134	
previously described.28 The score was attributed as shown in table 1.  135	
 136	
RNA Extraction and qRT-PCR  137	
Colons were frozen in liquid nitrogen and stored at -80°C. Tissues were homogenized using 138	
TissueLyser (Qiagen, Valencia, CA), and mRNA was isolated using the Qiagen RNeasy Mini 139	
Kit (Basel, Switzerland) according to the manufacturer’s instructions. cDNA synthesis was 140	
performed using 1.5µg of mRNA which was reverse transcribed using PrimeScript RT 141	
reagent kit according to the manufacturer’s instructions (Takara Bio Inc Japan). Real-time 142	
PCR was performed using Power SYBRgreen PCR Master Mix (Applied Biosystems) and 143	
run using Applied Biosystems 7500 Fast (Carlsbad, CA). Each measurement was performed 144	
as duplicate. Quantification of fluorescence was normalized to Gapdh. Primers for IL-6, 145	
TNFa, TGFb1, PAR2, iNOS, and Gapdh were previously described.29-32 The sequences of the 146	
primers used were the following: IL-1b_F: 5’-CCT TGT GCA AGT GTC TGA AGC-3’, IL-147	
1b_R: 5’-TCA GAC AGC ACG AGG CAT TT-3’ ; IL-10_F : 5’-GTT GCC AAG CCT TGT 148	
CAG AAA-3’, IL-10_R : 5’-TTT CTG GGC CAT GGT TCT CT-3’ ; IL-12_F : 5’-CCG GTC 149	
CAG CAT GTG TCA AT-3’, IL-12_R : 5’-CAC TTG GCA GGT CCA GAG AC-3’ ; IL-150	
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18_F : 5’-ACC GCA GTA ATA CGG AGC AT-3’, IL-18_R : 5’-CGT TGG CTG TTC GGT 151	
CGA TA-3’ ; matriptase_F : 5’-ACA GTC CCT ACC CAG CTC AT-3’, matriptase_R : 5’-152	
GCA GAA CTT CTC CCC GTT GA-3’ ; MMP3_F : 5’-CTG CGG GGA GAA GTC TTG 153	
TT-3’, MMP3_R : 5’-TGT TGG ATG GAA GAG ACG GC-3’ ; CXCL2_F : 5’-GCG CCC 154	
AGA CAG AAG TCA TA-3’, CXCL2_R : 5’-CAG GTA CGA TCC AGG CTT CC-3’. 155	
 156	
Protein extraction, SDS-PAGE and Western blot analysis 157	
Colons were subjected to homogenization as previously described,33,34 in 1ml RIPA buffer 158	
(Tris pH 7.2 50mM, NaCl 150mM, NP40 1%, SDS 0.1%, Na-deoxycholate 0.5%, protease 159	
inhibitors 1mM [aprotinin + leupeptin + pepstatin, Complete Mini, Roche], PMSF 1mM) 160	
using TissueLyser (Qiagen). After 15 minutes centrifugation at 13000 rpm at 4°C, the 161	
supernatant was recovered and analyzed for protein content by Bradford assay, and pellet 162	
containing muscle tissue was discarded. 30µg of proteins were separated by SDS-PAGE on 163	
10% acrylamide gels, and proteins were electrically transferred to PolyScreen PVDF 164	
hybridization transfer membranes (Perkin Elmer, Boston, MA). Membranes were incubated 165	
overnight at 4°C with primary rat antibody for a-ENaC (1:500), b- and g-ENaC (1:1000),35 166	
NHE1 (1:500) and NHE3 (1:10) (kindly provided by Dr. Daniel Fuster, University of Bern, 167	
Switzerland), Na+, K+-ATPase (1:10000),36 occludin (1:1000, Invitrogen 71-1500), claudin-1 168	
(1:1000, Invitrogen 71-7800), ZO-1 (1:1000, Invitrogen 61-7300) and b-actin (1:1000, 169	
Sigma-Aldrich) and for 1 hour with donkey anti-rabbit IgG HRP-conjugated secondary 170	
antibody (1:10000, Amersham, Burkinghampshire, UK) (all antibodies in TBS-Tween 1% 171	
and dried milk 2%). The signal was revealed using SuperSignal West Dura detection system 172	
(Pierce, Rockford, IL) and quantified using ImageStudioTM Lite program (LI-COR). Kidney 173	
extracts from inducible renal-tubule specific Scnn1a KO mice,37 generated by interbreeding of 174	
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Scnn1alox/lox mice38 and Pax8::rtTA;TRE::LC1 mice,39 were used as negative controls for 175	
Scnn1a. The same strategy was used for Scnn1b and Scnn1g negative controls.40 176	
 177	
Transepithelial measurements 178	
Colon preparations were prepared as previously described.41 Briefly, proximal and distal 179	
colon were dissected and opened longitudinally along the mesenteric border. The outer 180	
smooth muscle layer was carefully removed with fine forceps and the colon preparation was 181	
mounted in Ussing chamber (0.3-cm2 surface area) bathed in standard Ringer solution (in 182	
mM: NaCl 119, NaHCO3 21, CaCl2 1.2, MgCl2 1.2, KH2PO4 0.6, K2HPO4 24, D-glucose 10) 183	
at 37°C and gassed with 95% O2 and 5% CO2 to maintain the pH at 7.4. The short circuit 184	
current (Isc, in µA) were measured using a computer-controlled voltage-clamp apparatus 185	
(VCC-600, Physiological Instruments, San Diego, CA). The transepithelial resistance (R, in 186	
Ω*cm2) were calculated according to Ohm’s law from 10 µA pulses of 20 ms duration. 187	
Amiloride-sensitive currents were obtained by adding 10 µM amiloride to the mucosal side. 188	
 189	
Statistical analysis 190	
Results are presented as mean ± SEM. Throughout the study, and if not otherwise stated, data 191	




frCR/frCR rats exhibit altered colon histology and increased levels of inflammatory markers 196	
without treatment 197	
In the present study, a detailed histopathological analysis of the colon in untreated frCR/ frCR 198	
animals with reduced colonic prostasin and ENaC activity further revealed presence of local 199	
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inflammation and angiodysplasia (Fig. 1) and a generally decreased number of goblet and 200	
crypt cells, as quantified by Alcian blue (AB) staining (Fig. 2A,B), and confirmed by periodic 201	
acid-Shiff (PAS) staining (data not shown). No histological alterations were observed in 202	
heterozygous animals (Fig. 1). The histology score to quantify the degree of intestinal 203	
inflammation was, however, not significantly different in the frCR/frCR mutant rats as compared 204	
to frCR/fr+ and wildtype controls (Fig. 3A).  205	
At the mRNA transcript expression level, the protease activated receptor 2 (PAR2), tumor 206	
growth factor β1 (TGFb1) and matrix metalloprotease 3 (MMP3) were significantly reduced 207	
(Fig. 4B,I,K), while inducible nitric oxide synthase (iNOS) appeared 4-fold increased as 208	
compared to wildtype animals (Fig. 4C), although no leucocyte and macrophage infiltrations 209	
were observable (Fig. 1). No differences could be detected for tumor necrosis factor a 210	
(TNFa), interleukin 1b (IL-1b), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 12 211	
(IL-12), interleukin 18 (IL-18), matriptase, and chemokine (C-X-C motif) ligand 2 (CXCL2) 212	
(Fig. 4A,D-H,J,L). Heterozygous mutant (frCR/+) rats showed intermediate mRNA transcript 213	
expression levels for these inflammation markers, being not significantly different from 214	
wildtype or homozygous mutant (frCR/frCR) rats (Fig. 4A-L). In summary, untreated 215	
homozygous frCR/frCR animals exhibited lower number of crypt and goblet cells and showed 216	
increased expression of iNOS, although the histology score to quantify intestinal 217	
inflammation was not significantly different among the groups. 218	
 219	
Untreated frCR/frCR rats display reduced NHE1 and NHE3 protein levels, but normal colonic 220	
permeability 221	
We investigated whether impaired colonic permeability might underlie the basal diarrhea and 222	
the observed histological changes. We analysed the protein expression levels of tight junction 223	
proteins in untreated animals. The protein levels of zona occludens 1 (ZO-1), occludin and 224	
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claudin-1 were not significantly changed between wildtype, heterozygous mutant (frCR/+) and 225	
homozygous mutants (frCR/frCR) (Fig. 5A-D). The transepidermal short circuit current (Isc) and 226	
the transepidermal resistance (TER) in untreated animals were not significantly different 227	
between the genotypes (Fig. 5H,I). The diarrhea score in homozygous mutant (frCR/frCR) rats 228	
was however significantly increased as compared to both wildtype and heterozygous (frCR/+) 229	
rats (Fig. 5J). We next analysed the protein levels of the sodium-hydrogen exchangers 1 and 230	
3 (NHE1 and NHE3) and the Na+,K+-ATPase in the colon of untreated animals. The protein 231	
expression levels of both NHE1 and NHE3 appeared significantly decreased in homozygous 232	
(frCR/frCR) mutants as compared to wildtype (Fig. 6A-C). The protein level of the Na+,K+-233	
ATPase was not changed between the genotypes (Fig. 6A,D). The protein expression levels 234	
of the full-length a-, b-, and g-ENaC subunits (Fig. 7A,B,D,E), and the cleaved a- and g-235	
ENaC fragments (Fig. 7C,F) were not different between wildtype and homozygous frCR/frCR 236	
animals. To summarize, untreated homozygous frCR/frCR animals showed no signs of altered 237	
colonic permeability, as evidenced by analysis of tight junction protein expression and TER, 238	
normal ENaC and Na+,K+-ATPase protein expression levels, but displayed reduced NHE1 and 239	
NHE3 protein expression levels. 240	
 241	
DSS treatment rapidly induces severe diarrhea and inflammation in frCR/frCR rats  242	
Induction of DSS-induced colitis equally lead to a slight but not significant body weight loss 243	
in all groups (Fig 8A). Already after 3 days of DSS treatment, homozygous mutant rats 244	
exhibited maximal diarrhea score and a significantly higher disease activity index that was 245	
maintained high throughout the (DSS) treatment (Fig. 8B,C). Control and heterozygous 246	
mutant animals developed increasingly severe diarrhea over the 7 days of treatment without 247	
ever reaching maximal diarrhea score (Fig. 8B); the disease activity index in frCR/+ animals 248	
was not significantly different from the wildtype group (Fig. 8C).  249	
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At the end of 7 days of DSS treatment, all groups showed an increase in the histology score 250	
that was significantly increased in the homozygous mutant rats as compared to the wildtype 251	
and heterozygous mutant rats (Fig. 3B). In all experimental groups, we observed a total 252	
decrease in the gland density, fibrosis of the submucosa and the lamina propria, and 253	
inflammatory infiltrates within gaps in the lamina muscularis mucosa (Fig. 9). In wildtype 254	
animals, the lamina muscularis mucosa appeared more frequently interrupted than in the other 255	
two groups, with mainly submucosal infiltrating macrophages, but overall an intact 256	
epithelium (Fig. 9). Heterozygous animals displayed muscular hypertrophy, shortened crypts, 257	
hyperplastic ganglia and an increased presence of lymphocytes (Fig. 9). In the homozygous 258	
mutant rats, a further striking decrease in the number of goblet cells (Fig. 2A,B) and 259	
rearrangements of the lamina propria (Fig. 9) were detected, and the overall inflammatory 260	
signs appeared more severe, with presence of neutrophils, eosinophils, and macrophages at 261	
the base of crypts, along with signs of cryptitis and edema of the lamina propria. Additionally, 262	
frCR/frCR animals presented ulcerations (Fig. 9). The mRNA transcript expression levels of 263	
TNFa, TGFb1, iNOS, IL-1b, IL-6, IL-12, IL-18, PAR2, matriptase, MMP3 and CXCL-2 were 264	
all highly increased in homozygous frCR/frCR  rats (Fig. 4A-E,G-L) as compared to both 265	
wildtype and heterozygous mutants, except for IL-10, where the mRNA transcript expression 266	
levels remained similar between the genotypes (Fig. 4F). Heterozygous frCR/+ animals 267	
showed similar mRNA transcript expression levels for all cytokines compared to wildtype 268	
animals (Fig. 4A-L).  269	
 270	
frCR/frCR rats exhibit severe bloody diarrhea and a delay in recovery  271	
At the end of the recovery phase, all groups regained weight; the gain was, surprisingly, 272	
significantly higher in frCR/frCR rats as compared to wildtypes (Fig. 8A). Although delayed, the 273	
disease activity index as well as the diarrhea score in the frCR/frCR group dropped down to 274	
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wildtype and heterozygous mutant values (Fig. 8B,C). Before, during, and after the treatment 275	
and recovery phase, the colon length gradually shortened in all groups, but was not 276	
significantly different between the genotypes (Fig. 8D). Following the recovery phase, all 277	
genotypes showed an increase in the histology score as compared to the score obtained after 7 278	
days of DSS treatment (Fig. 3C). Following recovery, we assessed the mRNA transcript 279	
expression levels of different inflammatory and remodeling markers in animals after 7 days of 280	
DSS treatment and 7 days of recovery. After 14 days of treatment, +/+, frCR/+ and frCR/frCR 281	
animals presented similar levels of mRNA transcript expression levels for TNFa, TGFb1, IL-282	
1b IL-6, IL-10, IL-12, IL-18, PAR2, matriptase, and MMP3 (Fig. 4A,B,D-K), whereas iNOS 283	
expression was about twice as high and CXCL2 expression 7-fold increased in the 284	
homozygous mutant rats as compared to the untreated frCR/frCR animals (Fig. 4C,L). Although 285	
not significantly different among the groups, the expression levels of TNFa appeared 286	
generally elevated in all genotypes as compared to untreated groups (Fig. 4A).  287	
 288	
The protein expression levels of sodium transporters are not altered in frCR/frCR rats following 289	
DSS treatment 290	
We further analyzed whether the severe diarrhea observed in homozygous mutants following 291	
DSS treatment and recovery phase could be correlated with a decreased ENaC or sodium 292	
transporter protein expression in the colon (Figs. 10 and 11). Surprisingly, at the protein 293	
expression level no differences could be detected between the groups neither for the sodium-294	
hydrogen exchangers 1 and 3 (NHE1 and NHE3), and the Na+, K+-ATPase (Fig. 10A-D), nor 295	
for the full-length a-, b-, and g-ENaC subunits (Fig. 11A,B,D,E), or the cleaved a- and g-296	
ENaC fragments (Fig. 11C,F). The Isc and the TER were not significantly different between 297	
wildtype and homozygous frCR/frCR mutant rats (Fig. 5H,I), despite a reduction in the protein 298	
level for ZO-1, but not for occludin and claudin-1 in frCR/frCR rats (Fig. 5E-G). 299	
	 13	
 300	
frCR/frCR rats exhibit severe architectural remodeling with crypt branching 301	
At the histological level, all genotypes displayed strongly decreased number of goblet cells 302	
(Fig. 2A,B), lesser crypts, absence of mucosecretory capacity of the epithelium, ulcerations, 303	
and architectural alterations with crypt branching; the latter was however less present in 304	
heterozygous animals (Fig. 12). Colons of wildtype animals still presented severe signs of 305	
acute inflammation, with increasing amounts of leucocytes and lymphocytes in the epithelium, 306	
edemas of the lamina propria, and presence of eosinophils, fibrine and pus in the lumen (Fig. 307	
12). Heterozygous animals showed milder signs of inflammation and ulceration, in most cases 308	
already re-epitheliarized, than wildtype and homozygous mutant rats (Fig. 12). Homozygous 309	
mutants reached a significantly higher score than both wildtype and heterozygous animals on 310	
day 14 (Fig. 3C). Here, the higher score of frCR/frCR rats reflected the strong architectural 311	
remodeling with high presence of branched crypts (Fig. 12). frCR/frCR rats displayed severe 312	
signs of inflammation and presence of pus in the lumen; additional localized angiodysplasia 313	
was observed (Fig. 12).  314	
In summary, prostasin seems to have a protective role against DSS-induced inflammation. 315	
Altered prostasin leads to increased and faster tissue remodeling following DSS treatment.    316	
 317	
Discussion 318	
frCR/frCR rats exhibit an intestinal/epithelial defect that affects the colonic integrity  319	
In the present study, we tested whether prostasin-mutant frCR/frCR rats, that show all signs of 320	
an epithelial dysfunction, are more prone to develop an experimentally DSS-induced colitis. 321	
We previously unveiled a lower body weight, an increased transepidermal water loss, and 322	
diarrhea.21 Body weight loss is often linked to dehydration defects caused by either skin or 323	
intestine anomalies as evidenced in human and rodents.42-44 A more detailed analysis in colon 324	
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of these frCR/frCR rats additionally unveiled a reduced number of crypt and goblet cells (Figs. 1 325	
and 2), that is indicative for a dysbalance of the intestinal homeostasis.45 Moreover, local 326	
inflammation could be observed together with mild edema, however without signs of 327	
infiltrating leucocytes or macrophages. Interestingly, the histological analysis of colon-328	
specific prostasin knockout mice shows no colonic alterations, and the mice are 329	
indistinguishable from the control group.24 There is no apparent effect on the number of crypt 330	
cells, a normal intestine length-to–body weight ratio, no leaky intestinal permeability 331	
following fluorescein isothiocyanate dextran supply in blood plasma, and no signs of 332	
increased stool hydration or diarrhea, indicating an overall intact intestinal barrier function.24 333	
This might be a tissue-specific phenomenon, since epidermis-specific prostasin (CAP1/Prss8) 334	
knockout mice display a severely impaired epidermal barrier function that results in 335	
significantly increased transepithelial water loss. These mice die shortly after birth due to a 336	
rapid and fatal dehydration through the skin.19 Complete absence of the tight junction protein 337	
occludin and leakiness of the tight junctions in the stratum granulosum are likely causative.19 338	
Alternatively, the G54-P57 deletion26 may induce additional effects through the modified 339	
interaction of prostasin with its potential effectors/targets, since we previously reported a 340	
considerable impact on the protein folding of the frCR/frCR mutation.21 Thereby, by comparing 341	
both prostasin mouse and rat mutants, a species- and tissue-specificity may account for our 342	
findings. fr/fr mice harboring a spontaneous V170D prostasin mutation that predicts a similar 343	
loss of protein stability as in frCR/frCR rats show no signs of colonic barrier dysfunction, like 344	
diarrhea or morphological alterations.21 Interestingly, untreated frCR/frCR animals did not show 345	
altered expression of tight junction proteins in the colon (Fig. 5A-D). Moreover, colonic Isc 346	
and transepidermal resistance were similar between wildtype and homozygous mutant 347	
animals without treatment (Fig. 5H,I). After recovery, despite reduced ZO-1 protein 348	
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expression (Fig. 5E), the Isc and TER were not changed between controls and frCR/frCR rats, 349	
indicating that the frCR mutation does not affect the colonic permeability.  350	
In normal human distal colon and rectum, electrogenic Na+ absorption (mediated by the 351	
epithelial Na+ channel, ENaC) is the dominant Na+ absorptive process and accounts for the 352	
substantial lumen-negative transmucosal electrical potential difference (PD).46 A loss of this 353	
PD is the hallmark of mucosal inflammation in active ulcerative colitis (UC), is proportional 354	
with impaired electrogenic Na+ absorption, and reflects marked dysfunction of apically 355	
located ENaC.14,47 Interestingly, ENaC-mediated electrogenic Na+ absorption is also markedly 356	
impaired in the non-inflamed sigmoid colon of patients with active CD of the terminal 357	
ileum.48 Thereby, down-regulation of ENaC with reduction in sodium reabsorption in colon 358	
was hypothetized to contribute to diarrhea associated with inflammatory bowel disease.14,48 In 359	
colon-specific (a)ENaC knockout mice, the morphology of the adult distal colon including 360	
colon epithelium and mucin-secreting goblet cells macroscopically appears to be normal 361	
without any effect on the number of crypt cells or difference in the intestine length-to-body 362	
weight ratio, or signs of diarrhea.24 As the amiloride-sensitive rectal potential difference is 363	
significantly reduced in frCR/frCR rats,21 we asked the question whether reduced ENaC activity, 364	
due to altered prostasin protein expression, is a predisposing factor to develop more rapidly 365	
and/or more severely a DSS-induced colitis.  366	
 367	
Prostasin protects against DSS-induced inflammation 368	
Although no leucocyte and macrophage infiltrations could be observed in untreated frCR/frCR 369	
rats, iNOS mRNA transcript expression levels were significantly increased, both with and 370	
without DSS treatment (Fig. 4C). In this context it is worthwhile mentioning that induced 371	
iNOS expression has been described to protect against pathogen infections.49 Equally, 372	
TGFb1, PAR2 and MMP3 mRNA transcript expression levels were significantly reduced (Fig. 373	
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3B,J,L). This decrease might be linked, since TGFb1 was previously shown to induce MMPs 374	
and PAR2 expression, and PAR2-mediated IL-6 secretion,50,51 even though here no change 375	
could be detected at the mRNA transcript expression level of IL-6 in untreated homozygous 376	
mutants and after DSS treatment and recovery (Fig. 4E). PAR-2 was previously identified as 377	
a downstream target of prostasin.43 It is expressed in mouse distal colon, and seems to 378	
stimulate Cl- and K+ secretion while inhibiting the baseline Na+ reabsorption.52 Even though 379	
PAR2 was previously identified as non-crucial in the pathogenesis of experimental DSS-380	
induced colitis, as tested in PAR2 knock-out mice,6 the receptor was shown upregulated in 381	
mast cells from patients with ulcerative colitis and Crohn’s disease.53,54 The mRNA transcript 382	
expression levels of PAR2 where indeed highly increased after 7 days of DSS treatment in 383	
homozygous mutants, but not significantly different after recovery (Fig. 4I).  384	
Following 7 days of DSS treatment, the wildtype, heterozygous and homozygous frCR/frCR 385	
animals showed signs of acute inflammation along with strong reductions in the number of 386	
goblet cells (Fig. 2), rearrangements of the lamina propria, and signs of fibrosis. However, the 387	
observed alterations were more severe in homozygotes, which also additionally presented 388	
edema and ulcerations (Figs. 3 and 9). This is consistent with the clinical parameters as 389	
described by Cooper and colleagues,27 revealing highest diarrhea score with rectal bleeding, a 390	
common symptom of IBD1, and highest disease activity index already at day 3 for frCR/frCR 391	
rats, while wildtype and heterozygotes never reached the maximal score (Fig. 8). This is also 392	
consistent with the mRNA transcript expression levels measured after 7 days of treatment. 393	
Colons of homozygous mutant animals displayed highly increased levels of all tested 394	
cytokines and remodeling markers as compared to both wildtype and heterozygous rats, 395	
except for IL-10 that remained similar among the genotypes (Fig. 4). Absence of IL-10 up-396	
regulation is in line with the increase of all other cytokines, since it exerts generally an 397	
immunoregulatory action on pro-inflammatory cytokines,55 like e.g. TNFa. The strong 398	
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increase in pro-inflammatory TNFa mRNA transcript expression that we could measure in 399	
homozygous mutants (Fig. 4A) is also a known feature in IBD, and TNFa-inhibitors are the 400	
most common drugs used in the treatment for UC.56 The increased mRNA transcript 401	
expression levels seen for IL-1b, IL-6, IL-12, IL-18 and TGFb1 in homozygous mutant 402	
animals (Fig. 4) are also observed in patients. Elevated mRNA transcript expression levels of 403	
IL-1b and IL-18 were measured in intestinal specimen from IBD patients.57-59 Currently, 404	
antibodies and agents targeting the pro-inflammatory IL-6 and IL-12 are studied in clinical 405	
trials.60 The anti-inflammatory cytokine TGFb1 was shown as strongly increased, but inactive 406	
due to blockade of its receptor by Smad7, leading to the development of Smad7-targeting 407	
agents for the treatment of IBD.61  408	
 409	
It is quite likely that decreased ENaC activity due to reduced prostasin expression is 410	
responsible for the severe watery diarrhea in homozygous mutant rats after DSS treatment. 411	
Similarly, other ion transporters have been linked to UC predisposition and pathogenesis, 412	
such as e.g. the sodium hydrogen exchanger 3 (NHE3), whose deletion in mice leads to 413	
elevated mortality during DSS-induced colitis.62 In patients suffering from IBD, several 414	
transporters including the Na+, K+-ATPase, NHE1, NHE3, β-ENaC, NHERF1,2, and CLC-5 415	
appear downregulated at the protein level.63 Similarly, down-regulation of sodium transporters 416	
and their associated regulatory proteins were observed in DSS- and TNBS- treated mice.63 417	
The authors stipulated that a coordinated down-regulation of multiple sodium transporters and 418	
their regulatory proteins might be responsible for IBD-associated diarrhea. In line with this 419	
observation, we could detect reduced protein expression for NHE1 and NHE3 in untreated 420	
homozygous frCR/frCR animals, while the levels for the Na+,K+-ATPase and a-, b-, and g-ENaC 421	
remained unchanged between genotypes (Figs. 6 and 7), although after treatment none of the 422	
protein expression levels was significantly different between the genotypes (Figs. 10 and 11). 423	
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Other proteases or regulatory proteins likely involved in the same cascade might be 424	
implicated as well. Intestine-specific deletion of matriptase, a proposed upstream activator of 425	
prostasin,64 results in lethality several weeks after weaning due to severe diarrhea and massive 426	
intestinal inflammation, resulting in complete breakdown of the mucosal barrier function and 427	
overall colonic architecture.65 During DSS-induced injury, matriptase is downregulated in 428	
wildtype mice as well as in colonic epithelium from IBD patients, and thus hypomorphic St14 429	
mice with low matriptase expression are severely delayed in recovering from DSS-induced 430	
colitis.6 Interestingly, also increased prostasin and/or matriptase expression may be causative 431	
for histological abnormalities, since the intestine-specific deletion of hepatocyte growth factor 432	
activator inhibitor 1 (HAI-1, also known as serine protease inhibitor Kunitz type 1 or 433	
SPINT1), an inhibitor of matriptase66 and prostasin as shown in vitro (Hummler et al., 434	
unpublished data), affects the intestinal integrity, worsening the colonic phenotype following 435	
DSS treatment.67 Interestingly, mutations in HAI-2 (or SPINT2) have been linked to a 436	
syndromic form of congenital sodium diarrhea in human patients,68,69 where prostasin-induced 437	
ENaC-mediated sodium currents are no longer inhibited.70 In this study, unlike in human 438	
samples,6 matriptase was highly increased at the mRNA transcript expression level in 439	
homozygous mutants after 7 days of treatment, but similarly expressed as in control animals 440	
without treatment and after recovery (Fig. 4J). This result suggests a more complex protease 441	
network, where upregulation of matriptase might be a compensation for mutated prostasin in 442	
rats. In summary, intact colonic sodium transport is required for intestinal integrity and 443	
transport alterations cause diarrhea that is one of the common symptoms of IBD. Lack of 444	
prostasin thus predisposes to the development of DSS-induced colitis, without however 445	
altering ENaC protein expression. Interestingly, after treatment and recovery, the amiloride-446	
sensitive Isc was completely abolished in both wildtype and homozygous frCR/frCR colons (data 447	
not shown). The same was observed in ex vivo epithelial preparations from UC patients, 448	
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where the response to amiloride was nearly completely absent, likely due to cytokine-induced 449	
downregulation of b- and g-ENaC.14 In our study, however, the protein expression levels of a-, 450	
b-, and g-ENaC were not different between the genotypes, both in untreated and in DSS-451	
treated animals (Figs. 7 and 11). In consensus with our data, cytokines can impact ENaC 452	
activity: TNFa is able to directly activate ENaC by binding to the C-terminal domain of a-453	
ENaC during pulmonary inflammation,71 whereas upregulation of TGFb1 drives 454	
internalization of ENaC during acute respiratory distress syndrome,72 likely via increased 455	
reactive oxygen species production.72,73 456	
 457	
Prostasin is required for the architectural integrity of the colon and protects from remodeling  458	
During the recovery phase, the diarrhea score and disease activity index gradually decreased 459	
in all genotypes over the 7 days of recovery with water (Fig 8), but were significantly delayed 460	
in the homozygous mutant frCR/frCR rats. Surprisingly, the body weight was even significantly 461	
higher in frCR/frCR rats as compared to wild-type at the end of the recovery phase (Fig. 8A). 462	
These observations are surprising since despite severe bloody diarrhea during 6 days (Fig. 463	
8B), and highly increased cytokine mRNA transcript expression levels during the treatment 464	
(Fig. 4), and although delayed, homozygous mutants achieved to recover to a similar level as 465	
wildtype and heterozygous frCR/+ animals. This might be a consequence of the basal 466	
inflammatory profile of the homozygous mutants, enabling them to recover in a more efficient 467	
way than wildtype and heterozygous rats. We could moreover measure increased mRNA 468	
transcript expression levels for the remodeling markers MMP3 and CXCL274 during the 469	
treatment in frCR/frCR animals (Fig. 4K,L), which might also contribute to the enhanced 470	
recovery. We previously reported in the skin of these rats mislocalisation of hair follicles.21 471	
Since this is an innate feature, there are no signs of acute inflammation in the epidermis of 472	
frCR/frCR mutant animals. In a similar way, we hypothesize that the inflammatory profile in the 473	
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colon of untreated homozygous mutants might be innate, potentially leading to habituation of 474	
the epithelium to local inflammations. Similarly, TGFb1-dependent down-regulation of T cell 475	
responses in patients was proposed to attenuate the response to harmless constituents of the 476	
endogenous microflora.75 Accordingly, the histopathological analysis revealed that frCR/frCR 477	
rats showed predominantly signs of chronic inflammation, together with important 478	
architectural modifications of the mucosa and the colonic epithelium; occasionally, we 479	
observed angiodysplasia (Figs. 1, 3 and 12). Wildtype and heterozygous mutants still 480	
displayed signs of rather acute inflammation, even though the observed features were milder 481	
in heterozygous rats compared to controls (Figs. 12 and 3). The evolution towards chronicity 482	
is thus more rapid in homozygous mutants than in wildtype and heterozygous animals. In line 483	
with this observation, we could measure in homozygous mutants highly increased mRNA 484	
transcript expression levels of CXCL2 (Fig. 4L), a proposed dysplastic and remodeling 485	
marker,76 that was strongly associated with dysplasia-carcinoma transition in human 486	
samples.77 Despite the fact that control and heterozygous rats displayed signs of acute 487	
inflammation, the mRNA levels for inflammatory markers were not different between the 488	
genotypes after recovery, except for iNOS that was significantly increased in frCR/frCR animals 489	
(Fig. 5).  490	
 491	
Taken together, these observations reveal a complex protease network where prostasin is 492	
implicated in the regulation of intestinal inflammation and susceptibility towards acute colitis. 493	
According to our results, prostasin is also implicated in this regulating network, and might be 494	
implicated in the protection against inflammation. Mutation of prostasin leads to reduced 495	
ENaC activity, NHE1 and NHE3 protein expression, and might increase inflammatory 496	
response. Therapies enhancing the protective activity of prostasin need further investigations 497	
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Table 1. Histological score to quantify the degree of intestinal inflammation according to 710	
Rath and colleagues.28 ­, increased ; ¯, decreased. 0.5 points were added to re-epitheliarized 711	




Figure 1. Representative H&E stained colon sections from untreated +/+, frCR/+, and frCR/frCR 715	
animals (n=4 per genotype). Magnification 10x scale bar = 50µm, and 20x scale bar = 25µm. 716	
The white box indicates the magnified zone of (angiodysplastic) blood vessels. Note the 717	
presence of shorter crypt cells and angiodysplasia in frCR/frCR rats ( * ). 718	
 719	
Figure 2. Representative Alcian blue stained colon sections from (A) untreated +/+, frCR/+, 720	
and frCR/frCR animals (untreated, upper panel), following 7 consecutive days of DSS treatment 721	
(7 days, middle panel) and following 7 days of DSS treatment and 7 days of recovery (14 722	
days, lower panel). Magnification 10x scale bar = 50µm. (B) Quantification of goblet cells 723	
from corresponding Alcian blue (AB)-stained colon sections from untreated (n=4 per 724	
genotype), following 7 days of DSS treatment (7 days, n=3 per genotype), and following 7 725	
days of DSS treatment and 7 days of recovery (14 days, n=5 per genotype). ** p< 0.01, *** 726	
p< 0.001. 727	
 728	
Figure 3. Histology score as determined (Rath et al. 1996) for (A), untreated +/+, frCR/+, and 729	
frCR/frCR animals (n=4 per genotype), (B), following 7 days of DSS treatment (7 days, n=3 per 730	
genotype), and (C), following 7 consecutive days of DSS treatment and 7 days of recovery 731	
(14 days, n=5 per genotype). ** p< 0.01, *** p< 0.001. 732	
 733	
Figure 4. Relative mRNA transcript expression levels of (A) TNFa, (B) TGFb1, (C) iNOS, 734	
(D) IL-1b, (E) IL-6, (F) IL-10, (G) IL-12, (H) IL-18, (I) PAR2, (J) matriptase, (K) MMP3, 735	
and (L) CXCL2 in colons from +/+, frCR/+, and frCR/frCR animals (untreated, n=4 per genotype), 736	
after 7 days of DSS treatment (7 days, n=3 per genotype) or following 7 consecutive days of 737	
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DSS treatment and 7 days of recovery (14 days, n=5 per genotype). * p< 0.05, ** p< 0.01, 738	
*** p< 0.001.  739	
 740	
Figure 5. (A) Representative immunoblots of colon lysates from untreated (left panel) and 741	
treated (7 days DSS and 7 days recovery, 14 days, right panel) +/+ and frCR/frCR rats with zona 742	
occludens (ZO-1), occludin, claudin-1 and actin. Protein quantification of corresponding 743	
immunoblots for untreated (B-D) and treated (14 days, E-G) animals for (B, E) zona-744	
occludens 1 (ZO-1), (C, F) occludin, and (D, G) claudin-1; n=6 for each genotype. Actin was 745	
used as loading control. (H) Short circuit current (Isc) and (I) transepidermal resistance (TER) 746	
in proximal and distal colon of +/+ and frCR/frCR animals (untreated, n=3 per genotype) or 747	
following 7 days of DSS treatment and 7 days of recovery (14 days, n=3 per genotype). (J) 748	
Diarrhea score in untreated +/+, frCR/+, and frCR/frCR animals (n=4 per genotype). * p< 0.05. 749	
 750	
Figure 6. (A), Representative immunoblots from colon lysates from untreated +/+, and 751	
frCR/frCR rats for NHE1, NHE3 and Na+, K+-ATPase; actin was used as loading control (n=6 752	
per genotype). (B-D) Corresponding protein quantification for (B), NHE1, (C), NHE3, and 753	
(D), Na+, K+-ATPase. * p< 0.05. 754	
 755	
Figure 7. (A), Representative immunoblots from colon lysates from untreated +/+, and 756	
frCR/frCR rats for a-ENaC, b-ENaC and g-ENaC; actin was used as loading control (n=6 per 757	
genotype) (B-F) Corresponding protein quantification for (B), full-length (FL) and (C), 758	
cleaved (Cl) a-ENaC, (D), full-length b-ENaC, (E), full-length (FL) and (F), cleaved (Cl) g-759	
ENaC subunits (n=6 per genotype). Protein extracts from inducible kidney-specific Scnn1a, 760	
Scnn1b and Scnn1g knock-out mice were used as negative controls for each immunoblot (Ctrl 761	
KO). Actin was used as loading control. 762	
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 763	
Figure 8. Determination of clinical disease parameters during the course of the experiment (7 764	
days of DSS treatment and 7 days of recovery) with (A), ∆ body weight as % of initial BW 765	
(g) from +/+ (n=8), frCR/+ (n=5), and frCR/frCR (n=8) rats. (B), diarrhea score from +/+ (n=8), 766	
frCR/+ (n=5), and frCR/frCR (n=8) animals. (C), disease activity index from +/+ (n=8), frCR/+ 767	
(n=5), and frCR/frCR (n=8) animals. (D), mean colon length of +/+, frCR/+, and frCR/frCR animals 768	
(untreated, n=4 per genotype), after 7 days of DSS treatment (7 days, n=3 per genotype), or 769	
following 7 days of DSS treatment and 7 days of recovery (14 days, n=5 per genotype). * 770	
p<0.05, ** p<0.01, *** p<0.001.  771	
 772	
Figure 9.  Representative H&E stained colon sections from +/+, frCR/+, and frCR/frCR animals 773	
following 7 days of DSS treatment (n=3 per genotype). Magnification 10x scale bar = 50µm, 774	
and 40x scale bar = 10µm. The white box indicates the magnified zone of inflammatory foci. 775	
† : inflammatory infiltrations, ‡ : hypertrophy, ¶ : fibrosis, ∆ : edema, # : acute ulcer, M : 776	
macrophage, E : eosinophil, N : neutrophil. 777	
 778	
Figure 10. (A), Representative immunoblots and corresponding protein quantification of (B), 779	
NHE1, (C), NHE3, and (D), Na+, K+-ATPase in colons from +/+, frCR/+, and frCR/frCR (n=5 780	
per genotype) rats following 7 days of DSS treatment and 7 days of recovery. Actin was used 781	
as loading control. 782	
 783	
Figure 11. (A), Representative immunoblots and corresponding protein quantification of (B), 784	
full-length (FL) and (C), cleaved (Cl) a-ENaC, (D), full-length b-ENaC, (E), full-length (FL) 785	
and (F), cleaved (Cl) g-ENaC subunits in colons from +/+, frCR/+, and frCR/frCR (n=5 per 786	
genotype) rats following 7 days of DSS treatment and 7 days recovery. Protein extracts from 787	
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inducible kidney-specific Scnn1a, Scnn1b and Scnn1g knock-out mice were used as negative 788	
controls for each immunoblot (Ctrl KO). Actin was used as loading control. 789	
 790	
Figure 12. Representative H&E stained colon sections from +/+, frCR/+, and frCR/frCR animals 791	
following 7 days of treatment plus 7 days of recovery (n=5 per genotype). Magnification 10x 792	
scale bar = 50µm, and 40x scale bar = 10µm. The white box indicates the magnified zone of 793	
inflammatory foci. † : inflammatory infiltrations, ∆ : edema, ∞ : crypt branching, # : acute 794	







0 1 2 3 4 
+0.5-+1 for 
each 
Inflammatory cells - ­ ­­ ­­­ ­­­ ulcer 
Goblet cells - ¯ ¯¯ ¯¯¯ ¯¯¯ 
Mucosa thickening - ­ ­­ ­­­ ­­­ 
Submucosa cell infiltration - - ­ ­­ ­­­ 
Destruction of architecture - - - ­ ­­ 
 
Table 1. Histological score to quantify the degree of intestinal inflammation according to 
Rath and colleagues.28 ­, increased ; ¯, decreased. 0.5 points were added to re-epitheliarized 
ulcers, and 1 point was added for acute ulcers. 












